Severely suppressed bone turnover: a potential complication of alendronate therapy.
about
Giant osteoclast formation and long-term oral bisphosphonate therapyBisphosphonates: mechanism of action and role in clinical practiceOsteoclasts: what do they do and how do they do it?Atraumatic intracapsular neck of femur fractures after prolonged bisphosphonate treatment: a new atypical variant?MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for OsteoporosisManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchAtypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral ResearchPathogenesis, management and prevention of atypical femoral fracturesThe Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled TrialsDo bisphosphonates cause femoral insufficiency fractures?Periprosthetic bone loss: diagnostic and therapeutic approachesBisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) projectNonsurgical Treatment Strategies after Osteoporotic Hip Fractures.Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and PreventionBisphosphonates: from bench to bedsideThe transcription factor T-box 3 regulates colony-stimulating factor 1-dependent Jun dimerization protein 2 expression and plays an important role in osteoclastogenesisComplex regional pain syndrome: a recent update.Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data.Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats.The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.Atypical Femoral Shaft Fractures in Female Bisphosphonate Users Were Associated with an Increased Anterolateral Femoral Bow and a Thicker Lateral Cortex: A Case-Control StudyIdentification and treatment of osteoporosis among elderly patients with hip fracturesAtypical femoral fracture risk in patients treated with bisphosphonates.Spinal Compression Fracture Management: A Review of Current Treatment Strategies and Possible Future Avenues.Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.Association between alendronate and atypical femur fractures: a meta-analysis.Long-Term Alendronate Use Not without Consequences?Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench.Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice.Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.Histology of 8 atypical femoral fractures: remodeling but no healingLateral Femoral Bowing and the Location of Atypical Femoral Fractures.Sanguinarine protects against ovariectomy‑induced osteoporosis in miceAtypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis.The effect of antiresorptives on bone quality.Diagnosis and management of mineral metabolism in CKD.Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.Safety of drugs used in the treatment of osteoporosis.Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.
P2860
Q24626459-21362467-0FC4-4D2D-8E2A-DD4AF4BFF9B0Q24644708-A636D244-6E99-4579-B51F-A770CBBEAEB9Q24683898-7DED0C72-A6D8-4133-AAF9-ACA53952C4F2Q26744060-6C4650AD-236F-4184-B841-17CB1DFAB992Q26752588-C17083F4-8496-4420-8CFC-ADBB535A6E39Q26782621-0EF4B87A-D1DA-4174-A4EE-BA742CC9FB3AQ26782834-CADA0928-9262-4EC4-B36B-AF3A14EE6B4FQ26824555-40F319BD-3D57-4A46-B2B8-92E550C27A0EQ27010303-F2A20735-3741-41EF-9DFF-D011D1856AF0Q27021396-8C6A4B26-C91E-41F8-9DCD-6BBD0B319600Q27024847-44EEECAA-1A05-4DB7-84E8-ECF638C4A6E0Q27026618-B9E95651-FF83-4930-8FC3-36EDDB8F19DAQ27693845-EF2DBB7B-00FA-411A-B356-B081B5B16404Q28079133-A5A4FFDD-D33A-47E5-9358-AE7851FD78DBQ28251212-92F708F3-2104-45C2-895F-467695FB2AE5Q28305297-1F877862-D814-4FBD-858A-3660D50FCCF3Q30238767-56D50766-3D01-4EC9-BBCE-E63E431B949CQ31026858-59FE770D-8261-4643-A654-71167658D299Q33252926-076B85E0-F317-4E69-B0A5-67B4C45921B8Q33268786-E79E85A2-6DF3-4924-B00F-A23FE07D9AE6Q33552108-F408F1FA-3136-4307-B5C9-E4D6C19081D1Q33555079-2C12CA9F-F636-47B5-8672-FB92F5CC1B6DQ33582253-A9FF6B49-584D-4991-89DD-E2B56F2B6F1DQ33590002-EBA07846-6B1B-4ECC-B8BF-B0A12E5EA264Q33594764-5AAA65C6-266D-4B0E-83E4-707181C6F565Q33596535-9D3170C4-2515-47DE-9FDF-5A98916AD569Q33633821-4160FF26-E714-4C99-B301-41C04C619107Q33666457-E4E7AC7F-2D14-476D-BCA1-C0EA0642EFF3Q33713146-ABF5AB60-7FC9-497C-B097-871990E595CAQ33715141-300E0E22-0B5B-41EA-8E1E-58FBA0D8DDC8Q33736180-4A056BD0-5B27-44BD-B6EC-78EAFE047A1DQ33774987-C49A3057-1462-4AB5-ABA3-4177F4935F2FQ33781081-8DED510E-D46A-41EE-9E87-88775A2B7532Q33828107-3B4EF45C-002F-42A6-BD4A-6EB8313523BEQ33844438-19B53FF7-0CCC-4D05-AEC4-2B722A043B77Q33896122-6AA57C01-A77D-4FFD-A876-23CA10301CBAQ33898681-DC607788-5149-4F95-A2A1-78007AB964A4Q33898842-6BDA3FBF-31C1-44FE-B948-6E210EE47C32Q33949479-C18CC6C1-15B7-4624-BF31-1BBAD0942AD2Q33958113-B43185C8-F9CE-41E4-B1EA-CB13D5C61B30
P2860
Severely suppressed bone turnover: a potential complication of alendronate therapy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Severely suppressed bone turnover: a potential complication of alendronate therapy.
@ast
Severely suppressed bone turnover: a potential complication of alendronate therapy.
@en
type
label
Severely suppressed bone turnover: a potential complication of alendronate therapy.
@ast
Severely suppressed bone turnover: a potential complication of alendronate therapy.
@en
prefLabel
Severely suppressed bone turnover: a potential complication of alendronate therapy.
@ast
Severely suppressed bone turnover: a potential complication of alendronate therapy.
@en
P2093
P356
P1476
Severely suppressed bone turnover: a potential complication of alendronate therapy.
@en
P2093
Charles Y C Pak
Clarita V Odvina
D Sudhaker Rao
Frank A Gottschalk
Joseph E Zerwekh
Naim Maalouf
P304
P356
10.1210/JC.2004-0952
P407
P577
2004-12-14T00:00:00Z